DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/m427tb/competitive) has announced the addition of the "Competitive Handbook towards Personalized Medicine in Prostate Cancer" report to their offering.
BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:
1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.
2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.
3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.
4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.
American Gene Technology International
Anavex Life Sciences
Cancer Research Technology
Human Genome Sciences
Ivy Medical Chemicals
Johnson & Johnson
Kyowa Hakko Kirin
For more information visit http://www.researchandmarkets.com/research/m427tb/competitive
Source: Research and Markets